ANDA 87021, held by Watson Laboratories. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 87021 (Procainamide Hydrochloride), held by Watson Laboratories, was first approved by FDA on Jul 17, 1980, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 17, 1980 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride500MG · capsule;oral | Procainamide Hydrochloride | Discontinued |
| Dec 9, 1991 | Supplement 22Labeling | Approved | None posted |
| Apr 26, 1991 | Supplement 21Labeling | Approved | None posted |
| Nov 29, 1988 | Supplement 20Labeling | Approved | None posted |
| Aug 12, 1988 | Supplement 19Labeling | Approved | None posted |
| Jul 17, 1980 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters